Amicus Gains Final Approval for BioMarin Acquisition Completion

Amicus ( (FOLD) ) has shared an update.

Amicus Therapeutics, Inc. entered into a merger agreement on December 19, 2025, with BioMarin Pharmaceutical Inc., under which a BioMarin subsidiary will merge with Amicus, leaving Amicus as a wholly owned subsidiary of BioMarin. On April 23, 2026, France’s Ministry of Economics and Finance granted the final required foreign direct investment clearance for the transaction, paving the way for the merger to close on April 27, 2026, a step that is set to fold Amicus fully into BioMarin’s rare-disease portfolio and streamline its future operations within the larger group.

The most recent analyst rating on (FOLD) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Amicus stock, see the FOLD Stock Forecast page.

Spark’s Take on FOLD Stock

According to Spark, TipRanks’ AI Analyst, FOLD is a Neutral.

The score is driven primarily by improving operating fundamentals and cash-flow inflection, but capped by balance-sheet leverage and lack of consistent profitability (negative P/E). Technicals are supportive yet overbought, while the BioMarin acquisition approval adds a meaningful positive catalyst tempered by remaining regulatory-close risk.

To see Spark’s full report on FOLD stock, click here.

More about Amicus

Amicus Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies, often for rare and genetic diseases, positioning itself within the specialty pharma segment of the healthcare industry. Its operations center on research, clinical development, and targeted treatments that address unmet medical needs in niche patient populations.

Average Trading Volume: 4,383,560

Technical Sentiment Signal: Buy

Current Market Cap: $4.54B

See more insights into FOLD stock on TipRanks’ Stock Analysis page.